Seres Therapeutics, Inc.

NasdaqGS:MCRB

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 79.47 M

Share Price

USD 9.10

Avg Daily Volume

90,689

Change (1 day)

-4.31%

Change (1 year)

-42.04%

Change (YTD)

-45.25%

Seres Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD -11.32

Seres Therapeutics, Inc. Free Cash Flow Per Share is USD -11.32 for the Trailing 12 Months (TTM) ending March 31, 2025, a 1,289.03% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Seres Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -0.81.
Seres Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -0.45, a -62.83% change year over year.
Seres Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -1.21, a 12.38% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio	Quick Ratio

NasdaqGS: MCRB

Seres Therapeutics, Inc.

CEO	Mr. Eric D. Shaff M.B.A.
IPO Date	June 26, 2015
Location	United States
Headquarters	200 Sidney Street
Employees	103
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.